This program is testing VX-440 in combination with tezacaftor and ivacaftor. VX-440 and tezacaftor (VX-661) are new CFTR correctors. Correctors are drugs designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once CFTR protein reaches the cell surface, ivacaftor helps facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell.

Status

A phase 2 study for people with CF who have two copies of the F508del CFTR mutation, or one copy of F508del and one copy of a minimal function CFTR mutation, was completed. No further development is planned at this time.

Sponsor

This program is sponsored by Vertex Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation. This program is being conducted within the Therapeutics Development Network (TDN).